Mosanna Therapeutics has raised €70.1M in Series A funding led by Pivotal bioVenture Partners and EQT Life Sciences, with other investors including Forbion and Norwest.
The funding will support the development of MOS118 through Phase 2 and the expansion of Mosanna's pipeline in sleep apnea treatment.
David Weber, Ph.D., has been appointed as the new CEO of Mosanna, bringing over 30 years of experience in biotech leadership to the company.
Mosanna Therapeutics aims to revolutionize the treatment of obstructive sleep apnea with its drug-based nasal spray alternative, MOS118, targeting upper airway muscles.